FIGURE S1. CONSORT Diagram



FIGURE S2. Summary of Inclusion and Exclusion Criteria

Inclusion Criteria
• Age 18-65 • Fluent and literate in English or Dutch • Provide written informed consent • Total $HRSD_{17}$ ≥16 • Meets DSM-IV* criteria for single or recurrent nonpsychotic MDD established by MINI Plus
Exclusion Criteria
• Suicidal ideation and/or tendencies, defined by a score ≥8 on Section C of the MINI Plus • History of bipolar disorder (I, II, not otherwise specified) (lifetime) • History of schizophrenia, schizoaffective disorder, or psychosis not otherwise specified (lifetime) • Current primary diagnosis of anorexia or bulimia, obsessive-compulsive disorder, or primary post-traumatic stress disorder • Known contra-indication for escitalopram, sertraline and/or venlafaxine-XR, or previous treatment failure at the highest recommended dose • Taking any medication that is contraindicated with escitalopram, sertraline, or venlafaxine-XR • Taking escitalopram, sertraline, or venlafaxine-XR in the current episode of MDD • Use of any non-protocol antidepressant drug or CNS drug (antipsychotic, anticonvulsant anxiolytic, clonidine) that cannot be washed out prior to participation • Has general medical condition that contraindicates protocol antidepressant treatments or interferes with protocol measurements (such as epileptic condition for EEG recording) • Substance dependence (including alcohol intake equaling 29 standard alcoholic drinks per week for males; >15 for females) in the past six months • History of brain injury or blow to the head that resulted in loss of consciousness for greater than five minutes • Severe impediment to vision, hearing and/or hand movement that is likely to interfere with completion of assessments, or with comprehension of instructions or study requirements • Participation in an investigational study within four months prior to baseline that could affect symptoms of MDD • Is pregnant or breast-feeding

TABLE S1. Comparison of Modified Intent-to-Treat (mITT) Sample and Excluded Patients

		mITT Sample		Excluded Patients with Genotypes			
Measure	**Level**	**Mean or Count**	**SD or %**	**Mean or Count**	**SD or %**	**t or χ^2**	**p**
Age		38.65	12.79	36.00	12.27	2.688	0.008
Gender (number of females)		392	57.39%	111	54.15%	0.551	0.458
Ethnicity						3.760	0.584
	Black	106	15.52%	37	18.05%		
	Hispanic	56	8.20%	19	9.27%		
	Mixed	26	3.81%	4	1.95%		
	Other	68	9.96%	23	11.22%		
	Unknown	3	0.44%	0	0.00%		
	White	424	62.08%	122	59.51%		
Years of Education	-	14.54	2.88	14.43	2.57	0.534	0.594
Duration of MDD (Age - age of first episode)	-	14.81	12.57	13.22	11.31	1.699	0.090
Age of first episode	-	23.28	12.11	22.08	11.95	1.244	0.214
Weight (Kg)	-	79.45	21.03	76.41	22.79	1.680	0.094
HDRS anxiety score	-	6.16	1.93	6.20	1.96	-0.281	0.779
Baseline HAMD severity	-	21.70	4.06	22.34	4.24	-1.917	0.056
Baseline QIDS severity	-	14.54	3.77	14.22	3.88	1.029	0.304